-
3 Things Deutsche Bank Likes About Agilent's Q3, And One Thing To Be Cautious Of
Wednesday, August 16, 2017 - 11:46am | 507Read More...Agilent Technologies Inc (NYSE: A)'s earnings report was strong enough for Deutsche Bank's Dan Leonard to maintain a Buy rating on the stock with a price target boosted from $66 to $68. Agilent's fiscal third-quarter earnings report highlighted the company's strong end market exposures, product...
-
5 Things That Stood Out In Another Beat And Raise Quarter From Agilent
Wednesday, August 16, 2017 - 9:47am | 454Read More...Shares of Agilent Technologies Inc (NYSE: A) gained more than 4 percent after the company reported a better-than-expected fiscal third-quarter earnings report. Jefferies' Brandon Couillard maintains a Buy rating on Agilent's stock after the earnings print with a price target boosted from $66 to $70...
-
Martin Shkreli Calls Merck CEO Ken Frazier 'Self-Indulgent,' 'Pathetic'
Tuesday, August 15, 2017 - 11:49am | 678Read More..."Pharma bro" Martin Shkreli has some harsh words for Merck & Co., Inc. (NYSE: MRK)'s CEO Ken Frazier after the executive distanced himself from President Donald Trump. Frazier is one of four executives who stepped down from the president's American Manufacturing Council after Trump's initial...
-
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
Thursday, August 3, 2017 - 10:29am | 317Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform...
-
'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts
Wednesday, July 26, 2017 - 4:33pm | 622Read More...Amgen, Inc. (NASDAQ: AMGN) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst M. Ian Somaiya downgraded Amgen's stock rating from Outperform to Market Perform...
-
Valeant's $930 Million iNova Pharma Sale Boosts Stock Price
Thursday, June 8, 2017 - 8:47am | 403Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) gained more than 3.5 percent early Thursday morning after the company announced the sale of one of its business units. Valeant has agreed to sell its iNova Pharmaceuticals business for $930 million to a group advised and managed by major...
-
Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year
Monday, May 15, 2017 - 11:10am | 375Read More...JPMorgan's Michael Weinstein upgraded shares of Johnson & Johnson (NYSE: JNJ) from Neutral to Overweight with a price target boosted from $133 to $140 despite underperformance over the past year. According to Weinstein, shares of JNJ have underperformed the past 12 months and showed investors...
-
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Thursday, April 6, 2017 - 1:08pm | 365Read More...Argus' Stephen Biggar initiated coverage of Sanofi SA (ADR) (NYSE: SNY) with a Buy rating and $50 price target as the company has moved past a challenging period. According to Biggar, Sanofi has suffered through a period in which two of its best selling drugs, Lantus (diabetes) and Plavix (...
-
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Thursday, March 23, 2017 - 8:19am | 355Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), the troubled Israel-based generic and specialty medicines developer, confirmed with Bloomberg a plan to lower expenses and better manage its debt. A Bloomberg report cited Israeli-based news sources Calcalist, which initially reported Teva...
-
Analyst: GW Pharma's GBM Was Validated
Tuesday, February 7, 2017 - 11:52am | 299Read More...Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) with a $208 price target following the company's "encouraging" Phase 2 glioama data report. Success In GBM As part of the Phase 2 study, 21 patients who were treated with GW's mixed THC:CD...
-
Allergan Gains 1.50% Following Q4 Beat, Company Updates On M&A Activity
Monday, February 22, 2016 - 9:51am | 327Read More...Shares of Allergan plc Ordinary Shares (NYSE: AGN) were trading higher by more than 1.50 percent on Monday after the company reported its fourth quarter results. Allergan said that it earned $3.41 per share in the fourth quarter on revenue of $4.2 billion. Wall Street analysts were expecting the...
-
Shares Of Catabasis Pharmaceuticals See-Saw Following Results Of Duchenne Muscular Dystrophy Study
Monday, January 25, 2016 - 2:15pm | 218Read More...Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB), a clinical-stage small-cap biopharmaceutical company, were highly volatile during Monday's trading session after the company
-
Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share
Friday, January 22, 2016 - 2:39pm | 169Read More...Shares of Agile Therapeutics Inc (NASDAQ: AGRX) plunged to a 52-week low of $6.01 on Friday after the company announced a public offering of 5.512 million shares of its common stock at a price of $6.35 per share. Agile Therapeutics' stock closed at $7.06 on Thursday. The company disclosed...
-
Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan
Wednesday, January 20, 2016 - 1:07pm | 125Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent at $87.87 on Wednesday following an unconfirmed report by Pharma Japan, a pharmaceutical industry news site in Japan. According to Pharma Japan, Gilead's Sovaldi and Harvoni are among a small handful of...
-
15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference
Tuesday, December 1, 2015 - 5:45pm | 553Read More...Piper Jaffray is hosting its 27th Annual Health Care Conference December 1-2 in New York. Public biotechnology, specialty pharmaceuticals, drug discovery, medical technology, and other health care services companies will take part in the event. The conference addresses important questions in...
